(Reuters) -Shares in Wegovy maker Novo Nordisk fell around 4% on Friday to their lowest since August 2021, after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States.

Friday's drop brings this week's losses for Novo to more than 30% - marking its worst-ever weekly fall - after it slashed its outlook for 2025 sales growth and appointed veteran insider Maziar Mike Doustdar as its new CEO.